| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
| Targets |
CHBO4 specifically targets human monoamine oxidase B (hMAO-B) with high selectivity over other enzyme targets. It acts as a reversible and competitive inhibitor, binding to the active site of the enzyme and preventing the oxidative deamination of monoamine substrates. The compound also exhibits reactive oxygen species (ROS) scavenging activity, which contributes to its neuroprotective effects by reducing oxidative damage in neuronal cells. This dual mechanism—enzyme inhibition and antioxidant activity—makes CHBO4 particularly attractive for Parkinson's disease research.
|
|---|---|
| ln Vitro |
In Vero cells, CHBO4 (10-500 µg/mL, 48 hours) is biosafe [1]. In Vero cells, CHBO4 (128.8 µg/mL, 10 minutes) can lower ROS production [1].
In biochemical assays, CHBO4 demonstrates potent inhibition of hMAO-B with an IC50 value of 0.031 μM and a Ki value of 0.010 ± 0.005 μM. The compound reduces cellular damage by scavenging intracellular reactive oxygen species (ROS). In cellular models, CHBO4 (10-500 μg/mL, 48 hours) shows biosafety in Vero cells, and at 128.8 μg/mL for 10 minutes, it reduces ROS generation in these cells. These data confirm its potent enzyme inhibition and antioxidant properties at the cellular level. |
| ln Vivo |
In vivo, CHBO4 is used as a research tool in animal models of Parkinson's disease. The compound is administered to investigate dopaminergic neuroprotection, neurodegeneration, and motor function. Its ability to cross the blood-brain barrier and selectively inhibit MAO-B in the brain makes it suitable for studying the effects of enhanced dopamine signaling and reduced oxidative stress in PD models. Behavioral assessments such as locomotor activity, rotarod performance, and apomorphine-induced rotation tests are commonly employed to evaluate functional outcomes in treated animals.
|
| Enzyme Assay |
The hMAO-B inhibitory activity is assessed using a fluorometric or radiometric enzyme assay. Recombinant human MAO-B enzyme is incubated with various concentrations of CHBO4 and a suitable substrate such as kynuramine or benzylamine. The reaction product is quantified by fluorescence spectroscopy or liquid scintillation counting. IC50 values are determined by fitting dose-response data to a four-parameter logistic model. For Ki determination, enzyme activity is measured at multiple substrate concentrations in the presence of varying inhibitor concentrations, and data are analyzed using Lineweaver-Burk or Dixon plots.
|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: Vero cells Tested Concentrations: 10-500 µg/mL Incubation Duration: 48 h Experimental Results: decreased cell viability percentage with the IC50 value of 128.8 µg/mL diminished cellular density, cellular shrinkage, and blebbing exposed to concentrations (100-300 µg/mL) in Vero cells Cellular ROS scavenging activity is evaluated in cultured cells such as Vero or neuronal cell lines. Cells are treated with CHBO4 at various concentrations (e.g., 128.8 μg/mL) for 10 minutes, followed by exposure to an ROS-inducing agent such as H₂O₂ or a pro-oxidant. Intracellular ROS levels are measured using fluorescent probes such as DCFH-DA (2',7'-dichlorofluorescein diacetate). Cytotoxicity is assessed using MTT or CellTiter-Glo assays after 48 hours of treatment at concentrations ranging from 10-500 μg/mL to determine the biosafety profile. |
| Animal Protocol |
In vivo efficacy is evaluated in rodent models of Parkinson's disease, such as MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) or 6-hydroxydopamine (6-OHDA)-induced neurotoxicity models. CHBO4 is administered via oral gavage or intraperitoneal injection at appropriate doses for a defined treatment period. Neuroprotective effects are assessed by measuring dopaminergic neuron survival in the substantia nigra via tyrosine hydroxylase immunohistochemistry, striatal dopamine levels via HPLC, and motor function via behavioral tests such as rotarod and open field tests.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for CHBO4 are not extensively reported in the available literature. However, as a small molecule with appropriate lipophilicity for blood-brain barrier penetration, the compound is expected to achieve brain exposure following systemic administration. Typical PK parameters such as half-life, clearance, volume of distribution, and oral bioavailability would be determined in rodents following intravenous and oral dosing. The compound is formulated in suitable vehicles such as DMSO, PEG400, or saline for administration in preclinical studies.
|
| Toxicity/Toxicokinetics |
Based on available information, CHBO4 demonstrates biosafety in Vero cells at concentrations up to 500 μg/mL. In animal models, the compound is generally well-tolerated at doses used for efficacy studies, with no significant toxicity reported. However, comprehensive toxicology studies including acute and repeated-dose toxicity, genotoxicity, and safety pharmacology assessments have not been published. As with any MAO-B inhibitor, potential adverse effects related to increased monoamine levels and tyramine interactions (cheese effect) should be considered, although selective MAO-B inhibitors typically have a better safety profile than non-selective MAO inhibitors.
|
| References | |
| Additional Infomation |
CHBO4 is a research compound developed for studying Parkinson's disease and other neurodegenerative conditions involving MAO-B dysregulation and oxidative stress. Its mechanism of action combines selective hMAO-B inhibition with ROS scavenging activity, providing neuroprotective effects through both enhanced dopamine availability and reduced oxidative damage. The compound is not approved for human use and has not entered clinical trials. It serves primarily as a pharmacological tool for understanding the role of MAO-B in neurodegeneration and for validating MAO-B as a therapeutic target. All applications are limited to preclinical research settings.
|
| Molecular Formula |
C15H10OFBR
|
|---|---|
| Molecular Weight |
305.1417
|
| Exact Mass |
303.99
|
| CAS # |
98991-32-3
|
| PubChem CID |
5376503
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.484
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
300
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C=CC(=O)C2=CC=C(C=C2)Br)F
|
| InChi Key |
JLKQXQSMJJGERH-XCVCLJGOSA-N
|
| InChi Code |
InChI=1S/C15H10BrFO/c16-13-6-4-12(5-7-13)15(18)10-3-11-1-8-14(17)9-2-11/h1-10H/b10-3+
|
| Chemical Name |
(E)-1-(4-bromophenyl)-3-(4-fluorophenyl)prop-2-en-1-one
|
| Synonyms |
CHBO4; CHBO-4; CHBO 4
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2772 mL | 16.3859 mL | 32.7718 mL | |
| 5 mM | 0.6554 mL | 3.2772 mL | 6.5544 mL | |
| 10 mM | 0.3277 mL | 1.6386 mL | 3.2772 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
